Cardiovascular & hematological disorders drug targets最新文献_第9页

Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked. 高血压患者血压控制的药理作用不容忽视。

Cardiovascular & hematological disorders drug targets Pub Date : 2016-01-01 DOI: 10.2174/1871529X16666160101122820

M. Ciulla, C. Benfenati, E. Gallazzi, P. Vivona, R. Meazza, F. Lombardi

{"title":"Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked.","authors":"M. Ciulla, C. Benfenati, E. Gallazzi, P. Vivona, R. Meazza, F. Lombardi","doi":"10.2174/1871529X16666160101122820","DOIUrl":"https://doi.org/10.2174/1871529X16666160101122820","url":null,"abstract":"Our vision of long-term treatment strategies for the prevention of target organ damage and eventually cardiovascular morbidity and mortality in essential arterial hypertension needs to be continually monitored and updated for at least three issues: 1--the achievement of target pressure required to obtain the expected benefit needs continuous monitoring, a dose adjustment of the drug and, often, the use of combination therapies; 2--the chronic use of certain drugs, even in combination, is associated with the possible onset of side effects; 3--increasing of population life expectancy is inevitably associated with in an increase in drugs use with the unavoidable occurrence of adverse drug reactions, some of which can interfere with blood pressure control. These issues, still poorly studied, pose considerable problems in applying proper strategies for prevention. In this review, we will evaluate the goals of antihypertensive therapy, and its weak spots, such as the frequent side effects, that lead to poor therapy compliance. Moreover, we will review the interactions between antihypertensive and drugs used for other common disease, and their importance in not achieving the expected blood pressure reduction.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80800177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates. 肿瘤转移和转移相关细胞粘附分子(包括碳水化合物)的器官偏好。

Cardiovascular & hematological disorders drug targets Pub Date : 2016-01-01 DOI: 10.2174/1871529X15666151102102551

T. Kawaguchi

{"title":"Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates.","authors":"T. Kawaguchi","doi":"10.2174/1871529X15666151102102551","DOIUrl":"https://doi.org/10.2174/1871529X15666151102102551","url":null,"abstract":"This review starts on one of our special interests, the organ preference of metastasis. We examined data on 1,117 autopsy cases and found that the organ distribution of metastasis of cancers of the lung, pancreas, stomach, colon, rectum, uterine cervix, liver, bile duct, and esophagus involved the lung, liver, adrenal gland, bone/bone marrow, lymph node, and pleura/peritoneum. Cancers of the kidney, thyroid, ovary, choriocarcinoma, and breast, however, manifested different metastatic patterns. The distribution of leukemia and lymphoma metastases was quite different from that of epithelial cancers. On the basis of experimental studies, we believe that the anatomical-mechanical hypothesis should be replaced by the microinjury hypothesis, which suggests that tissue microinjury induced by temporal tumor cell embolization is crucial for successful metastasis. This hypothesis may actually reflect the so-called inflammatory oncotaxis concept. To clarify the mechanisms underlying metastasis, we developed an experimental model system of a rat hepatoma AH7974 that embraced substrate adhesiveness. This model did not prove a relationship between substrate-adhesion potential and metastatic lung-colonizing potential of tumor cells, but metastatic potential was correlated with the expression of the laminin carbohydrate that was recognized by Griffonia (Bandeiraea) simplicifolia isolectin G4. Therefore, we investigated the relationship between carbohydrate expression profiles and metastasis and prognosis. We indeed found an intimate relationship between the carbohydrate expression of cancer cells and the progression of malignant tumors, organ preference of metastasis, metastatic potential of tumor cells, and prognosis of patients.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91413143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management. 妊娠并发症中的炎症和血栓形成:风险评估和临床管理的意义。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-11-30 DOI: 10.2174/1871529X16666160101122530

F. La Farina, V. Raparelli, L. Napoleone, F. Guadagni, S. Basili, P. Ferroni

{"title":"Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management.","authors":"F. La Farina, V. Raparelli, L. Napoleone, F. Guadagni, S. Basili, P. Ferroni","doi":"10.2174/1871529X16666160101122530","DOIUrl":"https://doi.org/10.2174/1871529X16666160101122530","url":null,"abstract":"In Italy, each year 500,000 couples refer to specialized centers due to reproductive problems. Among them, recurrent pregnancy loss (RPL) represents a problem of great importance, given that it affects up to 5% of women of childbearing age. Infertility, on the other hand, is a condition that currently covers 10-20% of couples of reproductive age, being idiopathic in 20% of cases. Accumulating evidence support the concept that changes of blood coagulation, generically defined as the presence of a thrombophilic state (congenital or acquired), are the basis of 40-70% of cases of multiple abortions or infertility. Several evidences support the hypothesis that endothelial dysfunction, a hallmark of a condition of low-grade inflammation, is one of the earliest manifestations of thrombotic phenomena. To date, it's believed that, while the antiinflammatory Th2 cytokines (i.e. interleukin-10) can exert a protective role in pregnancy, the pro-inflammatory Th1 ones (i.e. interferon-γ, tumor necrosis factor-α,) have deleterious effects on pregnancy outcome, including fertilization and implantation failure. Moreover, development of many pregnancy complications, first and foremost venous thromboembolism (VTE), recognizes similar mechanism(s). As VTE is the main preventable cause of mortality during pregnancy, thromboprophylaxis is mandatory according to individual VTE risk, influenced by the presence of thrombophilic conditions. In this review, we will analyze the relationship between thrombophilia and pregnancy complications, with particular focus on the role of inflammation. Subsequently, we will consider some issues related to the thromboembolic risk in pregnancy. Finally, the role of thromboprophylaxis in pregnancy will be discussed.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77743568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

New Oral Anticoagulation after Heart Valve Replacement. 心脏瓣膜置换术后新的口服抗凝剂。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209111735

I. El-Battrawy, S. Baumann, A. Huseynov, I. Akin

引用次数: 1

Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management. 新型口服抗凝剂:对患者评估、治疗开始、随访和围手术期管理的建议。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209113125

S. Baumann, A. Huseynov, I. El-Battrawy, M. Renker, I. Akin

{"title":"Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management.","authors":"S. Baumann, A. Huseynov, I. El-Battrawy, M. Renker, I. Akin","doi":"10.2174/1871529X1502151209113125","DOIUrl":"https://doi.org/10.2174/1871529X1502151209113125","url":null,"abstract":"New oral anticoagulants (NOACs) are becoming available as alternatives to vitamin K antagonists (VKAs) to prevent systemic embolism in patients with non-valvular atrial fibrillation for the prevention and treatment of venous thromboembolism and pulmonary embolism. A comprehensive understanding of the basic concepts of hemostaseology, the underlying pharmacology, drug interactions and management of potential complications is essential for the selection of suitable patients to receive NOACs, for correct prescription and for optimal patient treatment. Furthermore, the use of NOACs in a perioperative setting is crucial, as it requires knowledge of time and dose of last intake of drug, current renal function and the planned procedure in order to assess the overall risk of bleeding. Although no antidote exists to reverse the effects of these novel drugs, selective substitution of coagulation factors and dialysis may be necessary. Therefore, choosing the most beneficial alternative to VKAs on an individual basis can be challenging for physicians. In conclusion, the recent introduction of NOACs represents an opportunity for anticoagulative treatment regimes, while the benefits, risks and limitations should be reflected carefully. The purpose of this systematic review is to highlight features and to provide practical guidance of NOACs in comparison with VKAs that should be considered in a multifaceted decision making process to improve efficacy and safety.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89937799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Novel Oral Anticoagulation--A Milestone in Anticoagulation History. 新型口服抗凝剂——抗凝史上的一个里程碑。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209124012

M. Yıldız, I. Akin

引用次数: 0

The Use of Novel Oral Anticoagulants in Atrial Fibrillation. 新型口服抗凝剂在房颤治疗中的应用。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209111019

U. Ansari, M. Behnes, C. Fastner, I. Akin

{"title":"The Use of Novel Oral Anticoagulants in Atrial Fibrillation.","authors":"U. Ansari, M. Behnes, C. Fastner, I. Akin","doi":"10.2174/1871529X1502151209111019","DOIUrl":"https://doi.org/10.2174/1871529X1502151209111019","url":null,"abstract":"Atrial fibrillation is known to be associated with an increased risk of ischaemic stroke and systemic embolism. After stratification using various risk calculation scores, patients were traditionally prescribed anticoagulants in the form of Aspirin or the traditional Vitamin K Antagonists. The use of Warfarin has proven to reduce incidents of ischaemic stroke; however its use has several limitations. The necessity for strict anticoagulation monitoring so as to maintain the narrow therapeutic range as measured by the international normalized ratio (INR) between 2 and 3 is one of these. In clinical practice, patients are within the therapeutic range lesser than two-thirds of the time and furthermore, its use is associated with a significant risk of major bleeding. The advent of Novel oral Anticoagulants marks a new era in anticoagulant therapy. The use of direct thrombin inhibitors and Factor Xa inhibitors has documented a favorable bleeding profile while being similarly or more efficacious when compared to VKA. Early studies indicate a significant reduction in the composite of stroke or systemic embolism and lowering of all-cause mortality. In this review we discuss the evidence for the clinical benefit and safety of the novel anticoagulants versus warfarin among patients with atrial fibrillation and probationary guidelines towards their use.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87328915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rationale for Development of New Oral Anticoagulants. 开发新型口服抗凝剂的基本原理。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209110044

M. Akin, J. Widder, I. Akin, M. Brehm, A. Schäfer

引用次数: 0

New Oral Anticoagulants in Coronary Artery Disease. 新型口服抗凝剂治疗冠状动脉疾病。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209111429

M. Behnes, C. Fastner, U. Ansari, I. Akin

引用次数: 4

Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis. 新型口服抗凝剂在静脉血栓栓塞治疗和血栓预防中的应用。

Cardiovascular & hematological disorders drug targets Pub Date : 2015-07-31 DOI: 10.2174/1871529X1502151209110620

M. Akin, A. Schäfer, I. Akin, J. Widder, M. Brehm

{"title":"Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.","authors":"M. Akin, A. Schäfer, I. Akin, J. Widder, M. Brehm","doi":"10.2174/1871529X1502151209110620","DOIUrl":"https://doi.org/10.2174/1871529X1502151209110620","url":null,"abstract":"Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thromboembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade's classic anticoagulants like heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists have been the gold standards in therapy and are widely used. Novel oral anticoagulants (NOAC) like the direct thrombin inhibitor (dabigatran etexilate) and the direct factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) have been introduced to overcome the drawbacks of vitamin K antagonists. The efficacy and safety of these NOAC have been investigated in several randomized trials. Here we want to give an overview about the NOACS in the treatment of acute and chronic VTE and their use for primary prevention of acute VTE.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75376850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14